velpatasvir (Epclusa) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central MeSH PubChem

Active Ingredient History

NOW
  • Now
Velpatasvir (VEL; GS-5816) is an inhibitor of HCV NS5A protein, it demonstrated favourable in vitro and in vivo properties, including potent antiviral activity against hepatitis C virus genotypes 1 to 6 replicon, good metabolic stability, low systemic clearance, and adequate bioavailability and physicochemical properties to warrant clinical evaluation. Velpatasvir is used together with sofosbuvir in the treatment of hepatitis C infection of all six major genotypes. A once-daily, single-tablet, pangenotypic regimen comprising the HCV NS5B polymerase inhibitor sofosbuvir and the HCV NS5A inhibitor velpatasvir (sofosbuvir/ velpatasvir; Epclusa) has recently been approved for the treatment of adults with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection in the USA, EU and Canada.   NCATS

Chemistry

  • SMILES: COC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C2=CC=CC=C2)C3=NC=C(N3)C4=CC5=C(C=C4)C6=CC7=C(C=C6OC5)C8=C(C=C7)N=C(N8)[C@@H]9CC[C@H](C)N9C(=O)[C@@H](NC(=O)OC)C(C)C
  • InChIKey: FHCUMDQMBHQXKK-CDIODLITSA-N
  • Mol. Mass: 883.0019
  • ALogP: 7.73
  • ChEMBL Molecule:
    velpatasvir  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Combination drugs

( sofosbuvir (sovaldi), velpatasvir (Epclusa) - other name: sofosbuvir and velpatasvir )
|
( sofosbuvir (sovaldi), velpatasvir (Epclusa), voxilaprevir (Vosevi) )

Alternative names

cdi-31244 | epclusa | gs5816 | gs-5816 | methyl {(2s)-1-[(2s,5s)-2-(9-{2-[(2s,4s)-1-{(2r)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1h-imidazol-4-yl}-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate | sofosbuvir / velpatasvir | sofosbuvir velpatasvir drug combination | sofosbuvir-velpatasvir drug combination | sofosbuvir, velpatasvir drug combination | sofosbuvir / velpatasvir / voxilaprevi | velpatasvir | velpatsvir

Organizations (80)

Research & Development (80)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (28)

Approved Indications (2)


 

Hepatitis C (approved 2016)

Hepatitis C, Chronic

Experimental Indications - Clinical Trial Phases 1-4 (28)


 

Bone Diseases, Metabolic (Phase 4)

Buprenorphine (Phase 4)

Carcinoma, Hepatocellular (Phase 4)

Coinfection (Phase 4)

Deglutition Disorders (Phase 1)

Drug Misuse (Phase 4)

End Stage Liver Disease (Phase 4)

Heart Failure (Phase 2)

Hepacivirus (Phase 1)

Hepatitis B, Chronic (Phase 4)

Hepatitis C (Phase 4)

Hepatitis C, Chronic ()

HIV (Phase 4)

HIV Infections (Phase 4)

Kidney Failure, Chronic (Phase 2)

Kidney Transplantation (Phase 2/Phase 3)

Liver Diseases (Phase 4)

Liver Transplantation (Phase 2)

Lung Diseases (Phase 1/Phase 2)

Lung Transplantation (Phase 4)

Methadone (Phase 4)

Neoplasms (Phase 4)

Opioid-Related Disorders (Phase 4)

Organ Transplantation (Phase 4)

Pharmacology (Phase 4)

Pregnancy Complications (Phase 4)

Respiratory Insufficiency (Phase 4)

Thalassemia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 92
  • # of Trial Organizations: 80

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue